House Committee Unveils Drug Development Incentives, FDA Regulatory Overhaul

Drug Industry Daily
The House Energy & Commerce Committee that oversees the FDA is planning an overhaul of agency procedures to increase orphan drug development, streamline clinical trials oversight, give industry incentives to find new uses for old drugs and expand U.S. drug manufacturing.

To View This Article:


Subscribe To Drug Industry Daily